ABBVIE INC. (ABBV) Financials
Key financial figures for ABBVIE INC. (Q2 2026).
AbbVie delivered Q2 2026 net revenues of $16.990 billion (+10.2% reported, +9.5% operational YoY) and adjusted diluted EPS of $3.65 (+22.9% YoY), driven by a 15.1% surge in the Immunology portfolio (Skyrizi $5.505B, Rinvoq $2.525B). Net revenues of $16.990 billion, up 10.2% on a reported basis (9.5% operational) versus Q2 2025 Adjusted diluted EPS of $3.65, up 22.9% YoY; GAAP diluted EPS of $2.03, up 290.4% YoY. Adjusted results include a $0.17/share unfavorable impact from acquired IPR&D and milestones expense Immunology portfolio revenue of $8.786 billion, up 15.1% reported (14.6% operational), led by Skyrizi ($5.505B) and Rinvoq ($2.525B); Humira continued its expected decline to $756 million on U.S. On the outlook: AbbVie updated its full-year 2026 adjusted diluted EPS guidance range from $13.91-$14.11 to $13.87-$14.07, reflecting an anticipated $0.14 per share dilutive impact from the proposed Apogee Therapeutics acquisition (expected to close in Q3 2026), partially offset by $0.10 per share of overperformance. Guidance includes a $0.58 per share unfavorable impact from acquired IPR&D and milestones expense incurred year-to-date through Q2 2026, and excludes any such expense beyond Q2 2026, which management said cannot be reliably forecasted. Figures are for Q2 2026, as AbbVie Inc. reported them.
- Revenue
- $17.0B
- Net Income
- $3.6B
- EPS
- $2.04
- Total Assets
- $135.1B
- Operating Cash Flow
- $3.4B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $17.0B | $3.6B | $2.04 | 37.86% | |
| Q1 FY2026 | $15.0B | $699M | $0.39 | 31.56% | $3.6B |
| Q4 FY2025 | $16.6B | $1.8B | $1.02 | 34.96% | $4.9B |
| Q3 FY2025 | $15.8B | $186M | $0.10 | 12.07% | |
| Q2 FY2025 | $15.4B | $938M | $0.53 | 31.73% | $4.9B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $61.2B | $4.2B | $2.37 | 32.85% | $17.8B |
| FY2024 | $56.3B | $4.3B | $2.39 | 16.22% | $17.8B |
| FY2023 | $54.3B | $4.9B | $2.72 | 23.49% | $22.1B |
Frequently asked questions
What was AbbVie Inc.'s revenue last quarter?
AbbVie Inc. reported revenue of $16.99 billion for Q2 FY2026, up 10.2% from the same period a year earlier.
Is AbbVie Inc. profitable?
Yes. AbbVie Inc. reported net income of $3.61 billion for Q2 FY2026, a net margin of 21.27% on revenue.
How has AbbVie Inc.'s margin trended?
Operating margin was 37.86% in Q2 FY2026, compared with 31.73% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How many quarters of AbbVie Inc. financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for ABBV. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for ABBVIE INC. on SentiSense, with up to forty quarters and twenty fiscal years of history.